[Individualized therapy with alpha-interferon in metastatic renal cell carcinoma].
Thirty-two patients with metastatic renal cell carcinoma were treated as outpatients with individually dosed interferon alpha (IFN alpha). The individual maximum dose was based on the side effects. In 7 patients the course of the disease was influenced: 1 attained complete remission, 3 patients, partial remission and 3, stable disease. The outcome of therapy was not dose-dependent. Patients with lung metastases were more sensitive to IFN alpha than the others. Up to 20% of patients responded to the therapy.